Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications Hans-Jürgen MöllerAndrea SchmittPeter Falkai Editorial 23 May 2016 Pages: 385 - 386
Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia Wolfram an der HeidenAnne LeberHeinz Häfner Original Paper 23 April 2016 Pages: 387 - 396
Neurocognitive impairment in the deficit subtype of schizophrenia Gagan FervahaOfer AgidGary Remington Original Paper 11 August 2015 Pages: 397 - 407
Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia Johannes RentzschAda StadtmannMaria Christiane Jockers-Scherübl Original Paper 17 July 2015 Pages: 409 - 421
Smaller than expected cognitive deficits in schizophrenia patients from the population-representative ABC catchment cohort Leonhard LennertzWolfram an der HeidenMichael Wagner Original Paper 02 August 2015 Pages: 423 - 431
The role of Pannexin gene variants in schizophrenia: systematic analysis of phenotypes Micha GawlikMartin WagnerGerald Stöber Original Paper 30 July 2015 Pages: 433 - 437
Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials Kazuto OyaYuki MatsudaNakao Iwata Original Paper 25 August 2015 Pages: 439 - 450
First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia Kjetil N. JørgensenRagnar NesvågIngrid Agartz Original Paper 07 November 2015 Pages: 451 - 460
Endurance training in patients with schizophrenia and healthy controls: differences and similarities Katriona Keller-VaradyAlkomiet HasanBerend Malchow Original Paper 05 November 2015 Pages: 461 - 473